|
Post by papihoyos on Jul 16, 2014 15:20:33 GMT -5
The value of the call who increase by $6 until the x-div date then if not closed out or excerzised you would be sol
|
|
|
Post by vissertrades on Jul 18, 2014 14:07:02 GMT -5
Wouldn't LLY's BIL pair well with AFREZZA?
Lilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes
Lilly expects U.S. and European regulatory submissions by Q1 2015
INDIANAPOLIS, May 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes. The primary efficacy endpoint of non-inferior reduction in hemoglobin A1c (HbA1c) compared to insulin glargine was met in all three trials. Having met the primary endpoints, superiority for HbA1c lowering was examined and, in all three trials, BIL showed a statistically superior reduction in HbA1c compared with insulin glargine.
The clinical trials evaluated three specific populations of patients with type 2 diabetes: those who were not previously taking insulin (IMAGINE-2); those taking basal insulin with mealtime insulin (IMAGINE-4); and those currently taking a basal insulin (IMAGINE-5). All three clinical trials compared BIL, an investigational basal insulin, with insulin glargine.
"These results are promising. Basal insulin peglispro is the first basal insulin to demonstrate consistently superior HbA1c reduction versus insulin glargine in Phase III clinical trials," said Enrique Conterno, president, Lilly Diabetes. "If approved, BIL could offer a differentiated profile and provide an important new treatment option for patients with diabetes. We are on track to make regulatory filings by Q1 next year."
These clinical studies also evaluated the secondary endpoints of nocturnal hypoglycemia rates and changes in weight. In all three clinical trials, patients taking BIL experienced statistically significant lower rates of nocturnal hypoglycemia than those taking insulin glargine. In addition, patients taking BIL had comparable to statistically significant less weight gain.
"In patients with type 2 diabetes taking insulin glargine, nocturnal hypoglycemia and weight gain may be barriers to improving glycemic control. The fact that patients treated with BIL had lower rates of nocturnal hypoglycemia and comparable to less weight gain while achieving superior improvements in glycemic control is noteworthy," said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes.
|
|
|
Post by bobw on Jul 21, 2014 5:57:37 GMT -5
OOG,
I am not sure what happens if the special dividend exceeds the strike price, but I am sure that it would not increase the number of shares that you have the right to purchase. In your example, it seems like you would be owed a $2 cash payment and the strike would be set to zero, but this is only a guess. I would expect that the calls would be marked to market and the call writer would have to post additional margin. If they are covered, the $2 would come from the dividend payment. Again, this is just an educated guess.
once the strike is zero, obviously, if you plan to hold the stock, they should be immediately exercised to start the long-term capital gains clock. It depends on your tax situation.
|
|
|
Post by mannmade on Jul 21, 2014 10:38:29 GMT -5
|
|
|
Post by kc on Jul 28, 2014 11:20:45 GMT -5
Something to remember from one of the June dog and pony shows that MannKind particiated in:
Reviewing One of the last Public MNKD Statement about Partners
Excerpt from transcript of mid June presentation:
"I do want to address one issue which is, surrounding commercialization, which is in fact the partner because that’s probably one of the most asked questions. And it’s part of the one I have the hardest time answering mostly because I am just not able to. We have said publicly we are in discussions with multiple parties, something always good to be in, but we don’t anticipate we are likely to announce a partnership before approval. So, how fast after approval? Well, that’s been a controversial question and in our recent conference appearance one of my colleagues went out a little bit on a limb and do this kind of a hypothetical number and said six to eight weeks that could be right, it could also be wrong. Could it be less? It absolutely could be less and we are hoping the people including some very well qualified bankers who have been working on this for many, many months with these same partners and working towards an agreement and are anxious to get this done, probably because we all like to get it done sooner so we can get it on the market quicker and probably because they are completely success based in their fees.
But at the end of the day we really can’t say. It’s quite likely or possible that there will -- the final partnering candidates will await for the final label and have a few things to want to hash over with us. So could it be days after approval? Yes, it could. Could it be months after? It could be that too. So I don’t want to set specific expectations, needless to say we’ll do it as quickly as we can and we think we’re pretty well equipped to do it pretty quickly after.
So summarizing and still leaving some time for questions we think this is a product clearly with blockbuster potential. Blockbuster is usually defined as anything over a billion and we can get that pretty easily with not very much of this market, actually frankly a very small percentage. And we think we have a new class of insulin therapy that addresses a very poorly met medical need in this space. We need better insulins, doctors universally agree we need them that work faster and have less risk of hypoglycemia. We think we can deliver on both those promises and we are anxious to be able to do that and that we could do it through a simple, easy to use, non-injection, and inhalation device that you can hide in the palm of your hand if you wish to, it’s just a icing on top of the cake in this regard."
|
|
|
Post by mrhaigs on Jul 29, 2014 6:29:07 GMT -5
What about Gilead or one of the newer big pharmas making their way on the scene? Gilead is strapped with cash after sovaldi is dominating and will continue to dominate.
|
|
|
Post by joeypotsandpans on Jul 29, 2014 7:38:04 GMT -5
Just an FYI on two mentioned potential partners
Merck's 2Q numbers out and beat expectations both top and bottom and raises outlook...Januvia sales 1.58 billion, PFE also beat on their numbers and plans on $5B share buyback...both are up pre market
|
|
|
Post by 1 percenter on Jul 29, 2014 8:13:04 GMT -5
Just an FYI on two mentioned potential partners Merck's 2Q numbers out and beat expectations both top and bottom and raises outlook...Januvia sales 1.58 billion, PFE also beat on their numbers and plans on $5B share buyback...both are up pre market I would love to see mnkd do a 250 million share buy back. Announce that just after partnetship deal. Dream on, right?
|
|
|
Post by liane on Jul 29, 2014 10:19:22 GMT -5
Just an FYI on two mentioned potential partners Merck's 2Q numbers out and beat expectations both top and bottom and raises outlook...Januvia sales 1.58 billion, PFE also beat on their numbers and plans on $5B share buyback...both are up pre market I would love to see mnkd do a 250 million share buy back. Announce that just after partnetship deal. Dream on, right? Won't happen at this point in time, but I can dream too!
|
|
|
Post by joeypotsandpans on Jul 29, 2014 10:27:35 GMT -5
I would love to see mnkd do a 250 million share buy back. Announce that just after partnetship deal. Dream on, right? Won't happen at this point in time, but I can dream too! The funny thing is it wouldn't even take 250m, 50m would do wonders most likely...hell I'd be happy to hear they didn't need the ATM for whatever reason. Now a buyback of 250m is way down the road...but substituting the word out or in could be much closer to a reality than a dream at this point
|
|
|
Post by liane on Jul 29, 2014 10:50:56 GMT -5
People make a big point of the existing share count at this time. I can easily see a significant buyback within a couple years, which of course will do wonders for my shares.
|
|
|
Post by papihoyos on Jul 29, 2014 12:39:03 GMT -5
No buy backs, MNKD will need the $$$ to develop the next 10 Afrezzas'. Afrezza is only the tip of the iceberg when you are speaking of Technophere application.
|
|
|
Post by seanismorris on Jul 29, 2014 12:53:48 GMT -5
I could care less about buying back stock...
I agree with the other poster, I want an expanded pipeline.
I want several partnerships to develope Technosphere opportunities, and do some of the simpler ones in house (using existing generics).
Do you want a 50B buyout in a few years? That's how we get there.
|
|